600216.SS
600216.SS
CNE0000010J2
ZHEJIANG MEDICINE
Loading chart...

Company Profile

Zhejiang Medicine Co., Ltd. manufactures and sells life nutrition and pharmaceuticals products in China and internationally. The company offers synthetic vitamin E, vitamin A, natural vitamin E, ß-carotene, canthaxanthin, vancomycin hydrochloride, teicoplanin, and daptomycin. It also provides fat-soluble vitamins, quinolone antibiotics, anti-drug-resistant antibiotics, and other products, as well as animal nutrition products. In addition, the company offers injectable levofloxacin lactate, vancomycin hydrochloride injection, and injectable teicoplanin products. The company was incorporated in 1997 and is headquartered in Shaoxing, China.

Related stocks

600211.SS
600211.SS • China
TIBET RHODIOLA PHARMACEUTICAL H
36.78 CNY
1.77B USD 1Y -22.9%
600267.SS
600267.SS • China
ZHEJIANG HISUN PHARMACEUTICAL C
11.94 CNY
2.11B USD 1Y +13.5%
603707.SS
603707.SS • China
NANJING KING-FRIEND BIOCHEMICAL
8.18 CNY
1.98B USD 1Y -21.6%
002099.SZ
002099.SZ • China
HISOAR
6.32 CNY
1.53B USD 1Y +8%
600572.SS
600572.SS • China
ZHEJIANG CONBA PHARMACEUTICAL C
4.41 CNY
1.68B USD 1Y +0.5%
002399.SZ
002399.SZ • China
HEPALINK
9.89 CNY
2.17B USD 1Y -16.7%
1681.HK
1681.HK • China
CONSUN PHARMA
14.85 HKD
1.59B USD 1Y -13.6%
603858.SS
603858.SS • China
SHANDONG BUCHANG PHARMACEUTICAL
14.81 CNY
2.34B USD 1Y -18.9%

Key Metrics & Overview

Detailed metrics & financial data of the company

Company Profile
5 Metrics

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High
5Y Volatility
34.1% p.a.
Max Drawdown (5Y)
-52.7%
Sharpe Ratio (5Y)
-0.24
Beta Factor
0.34
Size Class
Large Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
🔴 Low analyst coverage – higher uncertainty in growth estimates & projections
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (34.1% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -61.1% in the extended horizon.
ende